Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,301 papers from all fields of science
Search
Sign In
Create Free Account
1,2-dibromo-2,4-dicyanobutane
Known as:
METHYLDIBROMOGLUTARONITRILE
, bromothalonil
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Allergens
Narrower (1)
Euxyl K 400
Broader (2)
Nitriles
Pharmaceutical Preservatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Kontaktallergene im aktuellen Zeitverlauf
A. Schnuch
,
J. Geier
,
H. Lessmann
,
W. Uter
,
J. Brasch
,
P. Frosch
2016
Corpus ID: 163626049
ZusammenfassungHintergrundDas allergische Kontaktekzem ist eine häufig auftretende Krankheit (Jahresprävalenz 7%). Fur präventive…
Expand
Review
2010
Review
2010
Quantifying human susceptibility to contact sensitization; risk assessments now and in the future
P. Friedmann
,
C. Pickard
Contact Dermatitis
2010
Corpus ID: 16705035
Assessment and quantification of the risk that a chemical will induce allergic contact sensitization presently depend heavily on…
Expand
2007
2007
A further characteristic of susceptibility to contact allergy: sensitization to a weak contact allergen is associated with polysensitization. Results of the IVDK *
A. Schnuch
,
J. Brasch
,
H. Lessmann
,
J. Geier
,
W. Uter
Contact Dermatitis
2007
Corpus ID: 24862026
Although genetic factors probably account for differences in susceptibility to contact allergy, they have not yet been identified…
Expand
2005
2005
Allergic Contact Dermatitis from Methyldibromoglutaronitrile
M. Bruze
,
B. Gruvberger
,
A. Goossens
,
M. Hindsén
,
A. Pontén
Dermatitis
2005
Corpus ID: 29654028
Background: Arriving at a diagnosis of allergic contact dermatitis is a multistep procedure including the establishing of contact…
Expand
2004
2004
Methyldibromoglutaronitrile in leave‐on products elicits contact allergy at low concentration
L. K. Pedersen
,
Tove Agner
,
E. Held
,
J. D. Johansen
British Journal of Dermatology
2004
Corpus ID: 11280511
Background The rapidly increasing level of contact allergy to methyldibromoglutaronitrile (MDBGN) in Europe is of concern. In…
Expand
2003
2003
Anal- und Palmarekzem durch Iodpropinylbutylcarbamat in feuchtem Toilettenpapier
R. Schöllnast
,
B. Kränke
,
Prof. Dr. W. Aberer
Der Hautarzt
2003
Corpus ID: 22996675
ZusammenfassungWir berichten über einen 63-jährigen Patienten mit einem ausgeprägten perianalen und palmaren Ekzem, als dessen…
Expand
1998
1998
Metabolic and dispositional fate of 1,2-dibromo-2,4-dicyanobutane in the male fischer 344 Rat.
John-Michael Sauer
,
Richard L. Smith
,
Jingqi Bao
,
M. Kattnig
,
R. Kuester
,
I. Sipes
Drug Metabolism And Disposition
1998
Corpus ID: 12694543
Studies were conducted to characterize the absorption, disposition, metabolism, and excretion of 1,2-dibromo-2,4-dicyanobutane…
Expand
1998
1998
Sulfhydryl-dependent biotransformation and macromolecular binding of 1,2-dibromo-2,4-dicyanobutane in blood.
J. Bao
,
J. Sauer
,
R. Smith
,
R. Kuester
,
M. Kattnig
,
I. Sipes
Drug Metabolism And Disposition
1998
Corpus ID: 13040264
1,2-Dibromo-2,4-dicyanobutane (BCB) is a broad-spectrum microbicide used commercially in consumer products. The objectives of…
Expand
1997
1997
Three cases of contact allergy after chemical burns from methylchloroisothiazolinone/methylisothiazolinone: one with concomitant allergy to methyldibromoglutaronitrile/phenoxyethanol.
E. J. Primka
,
James S. Taylor
American Journal of Contact Dermatitis
1997
Corpus ID: 26812340
Review
1995
Review
1995
Patch testing with preservatives at St John's from 1982 to 1993
M. Jacobs
,
I. White
,
R. Rycroft
,
N. Taub
Contact Dermatitis
1995
Corpus ID: 29889017
We have reviewed our patch test results for preservative allergy from 1982 to W3. 8 preservatives were included: formaldehyde. 2…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE